Seegene

Seegene Intangible Assets

The Intangible Assets of Seegene (096530.KQ) as of Oct 28, 2026 is 23.30 B KRW. In the previous year, Intangible Assets was 10.32 B KRW — a change of 125.74% (higher).

Intangible Assets

23.30 BKRW

YoY

125.74%

Last updated:

Intangible Assets of Seegene is 2022 23.30 B KRW. Intangible Assets of Seegene was 2021 10.32 B KRW. It decreases by 125.74% higher compared to the previous year.

The Seegene Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
17.97 B KRW
Jan 1, 2016
19.73 B KRW
Jan 1, 2017
5.12 B KRW
Jan 1, 2018
4.93 B KRW
Jan 1, 2019
5.54 B KRW
Jan 1, 2020
5.58 B KRW
Jan 1, 2021
10.32 B KRW
Jan 1, 2022
23.30 B KRW
The Seegene Intangible Assets history
YEARIntangible AssetsYoY
23.30 BKRW+125.74%
10.32 BKRW+85.09%
5.58 BKRW+0.72%
5.54 BKRW+12.24%
4.93 BKRW-3.71%
5.12 BKRW-74.03%
19.73 BKRW+9.77%
17.97 BKRW+3.87%
17.30 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Intangible Assets of Seegene is 23.30 B KRW in 2022.

Intangible Assets of Seegene changed from 10.32 B KRW to 23.30 B KRW, representing a 125.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Seegene since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seegene

All Key Metrics — Seegene